Navigation Links
Onyx Pharmaceuticals Reports First Quarter 2011 Financial Results
Date:5/4/2011

Global Nexavar net sales, which are recorded by Onyx's collaborator, Bayer HealthCare Pharmaceuticals Inc., or Bayer, were $235.5 million for the first quarter 2011, an increase of $21.1 million, or 10%, compared to $214.4 million for the same period in 2010.  Onyx and Bayer are marketing and developing Nexavar® (sorafenib) tablets, an anticancer therapy currently approved for the treatment of unresectable liver cancer and advanced kidney cancer in over 100 countries worldwide.

For the first quarter 2011, Onyx reported total revenue from collaboration agreement of $67.1 million compared to $62.9 million for the same period in 2010. The increase in revenue from collaboration agreement between periods resulted primarily from higher net sales of Nexavar.

Operating ExpensesOnyx recorded research and development expenses of $62.5 million in the first quarter 2011 compared to $43.6 million for the same period in 2010. Research and development expense includes a $12.7 million non-cash expense related to the remaining balance of the funding provided to S*BIO in May 2010. The remaining increase in research and development expense was primarily due to investments in the development of carfilzomib, particularly the Phase 3 ASPIRE and FOCUS trials.  

Selling, general and administrative expenses were $34.5 million in the first quarter 2011, compared to $24.7 million for the same period in 2010.  Higher selling, general and administrative expenses between periods were primarily due to planned increases in employee headcount and related costs, legal costs, pre-launch costs for carfilzomib and increased facilities-related costs.  

Onyx recorded $11.5 million of non-cash contingent consideration expense in the first quarter 2011 associated with changes in the fair value of the liability for contingent consideration recorded for the potential milestone payments under the Proteolix acquisition. The increase i
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... LONDON , Aug. 20, 2014 Reportbuyer.com ... Global Cardiac Defibrillators Industry https://www.reportbuyer.com/product/98394/Global-Cardiac-Defibrillators-Industry.html ... Cardiac Defibrillators in US$ Million by the following Product ... provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ...
(Date:8/20/2014)... 20, 2014 Research and Markets  has announced ... report to their offering. Global Market ... on Pralmorelin globally and regionally ( Europe , ... , Latin America etc.). It captures ... This report focuses on three primary areas; manufacture methods & ...
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group ... and ablation device market will expand through ... treat atrial fibrillation (AF). The increasing acceptance ... for AF will spur adoption of premium-priced ... as advanced loop diagnostic catheters, cryoablation catheters ...
Breaking Medicine Technology:Global Cardiac Defibrillators Industry 2Global Cardiac Defibrillators Industry 3Global Cardiac Defibrillators Industry 4Global Cardiac Defibrillators Industry 5Global Cardiac Defibrillators Industry 6Global Cardiac Defibrillators Industry 7Global Cardiac Defibrillators Industry 8Global Cardiac Defibrillators Industry 9Global Cardiac Defibrillators Industry 10Global Cardiac Defibrillators Industry 11Global Cardiac Defibrillators Industry 12Global Cardiac Defibrillators Industry 13Global Cardiac Defibrillators Industry 14Global Cardiac Defibrillators Industry 15Global Cardiac Defibrillators Industry 16Global Cardiac Defibrillators Industry 17Global Cardiac Defibrillators Industry 18Global Cardiac Defibrillators Industry 19Global Cardiac Defibrillators Industry 20Global Market Report of Pralmorelin 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3
... WASHINGTON, Oct. 31 The following is being,issued by ... will hold a news conference about the lawsuit it ... Agriculture (USDA),to prevent the agency from allowing into the ... cattle over 30 months (OTM) of age,scheduled to begin ...
... Vice President of Scientific Affairs Dr. Randy Huffman ... Fund report, slated for,release October 31. Dr. Huffman ... WCRF,s 9:30 a.m. press conference., The American ... largest,association representing U.S. meat and poultry packers and ...
Cached Medicine Technology:R-CALF United Stockgrowers of America: 'Fighting for the U.S. Cattle Producer' 2
(Date:8/20/2014)... Salt Lake City, Utah (PRWEB) August 20, 2014 ... the Inc. 500’s 2014 list of the nation’s fastest growing ... overall growth in the health care sector. Connexion Point is ... specializes in contact centers in Medicare and Medicaid, and its ... in the nation. Connexion Point employs 1,000 people and has ...
(Date:8/20/2014)... amygdala stimulates stress responses in adults, researchers at ... found that the amygdala has an inhibitory effect ... nonhuman primates. , The results are published this ... The amygdala is a region of the brain ... situations and learning about threats. Alterations in the ...
(Date:8/20/2014)... 2014 (HealthDay News) -- New research reveals that, long ... the global spread of the infectious disease known as ... in Africa to seals and sea lions, who then ... years ago, according to an international team of researchers. ... rise again worldwide. This study and further research will ...
(Date:8/20/2014)... New York, US (PRWEB) August 20, 2014 ... advocate, market access, governmental and physician stakeholders networks ... Europe, Asia-Pacific, Latin America, US, Canada, and Emerging ... view into Heartbeat Experts’ perspectives on stakeholder management ... highlighted several new immunotherapy and targeted therapy investigational ...
(Date:8/20/2014)... TX (PRWEB) August 20, 2014 The ... Surgery (ACPS), has expanded its presence throughout Houston to ... Mann Eye Institute and Laser Center building. ACPS plastic ... natural step forward for ACPS, which has risen to ... plastic surgery practices in the state since its establishment ...
Breaking Medicine News(10 mins):Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 3Health News:Seals, Sea Lions Helped Global Spread of TB, Study Finds 2Health News:Download HeartBeat Experts White Paper: A Stakeholder Engagement Strategy is Critical for the Evolving Melanoma Treatment Setting 2Health News:Aesthetic Center for Plastic Surgery Expands Its Reach in Texas 2
... significantly decreases their ability to regulate blood-sugar levels and ... at the University of Chicago Medical Center in the ... of Science, available online as soon as Dec. 31, ... is thought to be the most restorative sleep stage, ...
... Alcohol and Drug Addiction ... Services Boards Merge, CANTON, Ohio, Dec. 31 ... Community Mental Health,Board and the Alcohol and Drug Addiction Services Board of ... Recovery Services Board,of Stark County., "The combined Board will create a ...
... you love and seek out support from friends, experts advise ... many Americans over 50 will resolve to start a new ... Aging offers tips for helping to keep that resolve: ... on starting an exercise program and to find out if ...
... YORK, Dec. 31 The New Year ... finally lose those excess pounds in a ... to this report from GlaxoSmithKline at:, http://media.medialink.com/WebNR.aspx?story=34274 ... audio, text, graphics and,photos for free and ...
... everyone uncork a merry celebration , , MONDAY, Dec. 31 (HealthDay ... of bubbly to celebrate the New Year, make sure you ... of Ophthalmology. , "A bottle of champagne can be ... popping the cork," Dr. Wayne Bizer, a clinical correspondent for ...
... 31 Ardea Biosciences,Inc. (Nasdaq: RDEA ) ... Agency (MHRA) in the United Kingdom has authorized ... non-nucleoside reverse,transcriptase inhibitor (NNRTI), in patients with human ... "There is a clear unmet need for new ...
Cached Medicine News:Health News:Lack of deep sleep may increase risk of type 2 diabetes 2Health News:Lack of deep sleep may increase risk of type 2 diabetes 3Health News:Combined Boards Provide Better Care to More Clients More Efficiently 2Health News:Make That New Year's Fitness Resolution Stick 2Health News:See to It That New Year's Eve Is Safe 2Health News:Ardea Biosciences' Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial 2Health News:Ardea Biosciences' Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: